Keytruda

Halozyme has won a Keytruda SC injunction in the Netherlands, ordering MSD to stop supplying the subcutaneous form of pembrolizumab in eight European markets. The case turned on how the patent's stability test is measured, and the injunction lapses country by country if a national court invalidates its part of EP 2 797 622. #SyenzaNews #oncology #patentlitigation #MarketAccess

Merck and Moderna's individualized neoantigen therapy intismeran has cleared its first Phase 3, beating KEYTRUDA alone in resected high-risk melanoma. The open question now is how payers value a medicine made for one patient at a time.

💰 Is pembrolizumab delivering high value for HNSCC in Switzerland? A new analysis confirms the immunotherapy offers strong cost-effectiveness, supporting smarter resource allocation and improved patient outcomes in oncology. Explore the full economic evaluation and its implications for market access. #SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

🔬 Can immunotherapy redefine outcomes in endometrial cancer? New data confirms pembrolizumab delivers a significant progression-free survival benefit for patients with dMMR endometrial cancer, strengthening its role in precision oncology and targeted treatment strategies. Read the full analysis to see how these findings could reshape clinical practice. #SyenzaNews #oncology #precisionmedicine #innovation

📈 How is Celltrion turning biosimilar momentum into stronger margins? The company’s Q2 results highlight robust growth across its biosimilar portfolio, driving improved profitability and reinforcing its competitive edge in global markets. Discover the full financial breakdown and strategic implications. #SyenzaNews #biotechnology #pharmaceuticals #innovation #MarketAccess

Could this FDA approval reshape care for patients with triple‑negative breast cancer? 🔬 The FDA has approved Keytruda (pembrolizumab) in combination therapy for TNBC, introducing a new immunotherapy option after clinical trials showed meaningful benefit for selected patients. This decision has important implications for clinicians, patients, and treatment access. Read the full article to understand the trial data, clinical impact, and market implications. #SyenzaNews #oncology #pharmaceuticals #innovation #MarketAccess

Can 5-year data finally change how we treat advanced melanoma? 🔬📈 The latest 5-year follow-up shows durable responses and meaningful survival benefits with contemporary melanoma therapies, while highlighting manageable long-term safety and the need for biomarker-driven treatment decisions. These findings have clear implications for clinicians, payers, and manufacturers planning access and long-term care strategies. Read the full article to explore the clinical takeaways, real-world implications, and what this means for treatment pathways and reimbursement. #SyenzaNews #oncology #drugdevelopment #MarketAccess #innovation

Could CHMP’s opinion on Keytruda and Padcev reshape perioperative care for bladder cancer? 🔬 A CHMP recommendation now highlights expanded perioperative use of pembrolizumab (Keytruda) and enfortumab vedotin (Padcev) for muscle‑invasive bladder cancer, signaling new neoadjuvant/adjuvant options that could lower recurrence risk and change treatment pathways. Read the full article for the trial evidence, regulatory next steps, and what this means for clinicians, payers, and patients. #SyenzaNews #oncology #pharmaceuticals #MarketAccess #innovation

Could immunotherapy finally change the game for ovarian cancer in Europe? 🔬 The EU has approved pembrolizumab (Keytruda) for a defined ovarian cancer indication, expanding treatment options and reshaping clinical practice, reimbursement and development strategies. This milestone will affect patients, payers and biotech planning across the region. Read the full analysis to understand who benefits, what it means for market access, and next steps for clinicians and industry. #SyenzaNews #oncology #pharmaceuticals #MarketAccess #healthcarepolicy

Could NICE's endorsement of pembrolizumab reshape care for resectable head and neck cancer? 🧬 NICE now recommends adjuvant pembrolizumab for patients at high risk of recurrence, signaling a move to bring immunotherapy into earlier treatment stages and impacting clinical pathways, reimbursement, and access across the UK. Learn what this means for surgeons, oncologists, payers, and patients. Read the full analysis for eligibility details, expected clinical impact, and market access implications. #SyenzaNews #oncology #pharmaceuticals #MarketAccess #healthcarepolicy

Could a Keytruda + Padcev combo change the survival outlook for muscle‑invasive bladder cancer? 🔬 The KEYNOTE‑B15 results report a meaningful overall survival benefit with this chemo‑sparing regimen in MIBC, highlighting promising efficacy and manageable safety that could shift treatment sequencing. Read the full breakdown of the data, clinical implications, and what this means for practice and access. 📈 #SyenzaNews #oncology #clinicaltrials #MarketAccess #innovation

Could late-breaking data from Keynote B15 redefine bladder cancer care? 🔬 Keynote B15 presented late‑breaking results on novel therapies and biomarker‑driven strategies that could shift treatment algorithms and refine patient selection. Read the full article to understand the clinical implications, what clinicians and payers should watch next, and how this may influence future trials. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess